Related Experiment Video
Updated: Jun 27, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Ropinirole prolonged release: in advanced Parkinson's disease
Juliane Weber1, Gillian M Keating
1Wolters Kluwer Health Adis, Auckland, New Zealand.
CNS Drugs
|December 10, 2008
Summary
Once-daily ropinirole prolonged release effectively reduces
Area of Science:
- Neurology
- Pharmacology
Background:
- Parkinson's disease is a neurodegenerative disorder impacting motor function.
- Dopamine receptor agonists, like ropinirole, are used in Parkinson's treatment.
- Ropinirole prolonged release offers a once-daily dosing option compared to immediate release.
Purpose of the Study:
- To evaluate the efficacy of ropinirole prolonged release in advanced Parkinson's disease.
- To compare once-daily ropinirole prolonged release with immediate-release formulations.
- To assess the safety and tolerability of ropinirole prolonged release.
Main Methods:
- Two randomized controlled trials were conducted.
- One trial used a placebo comparator; the other used ropinirole immediate release.
- Efficacy was measured by reduction in 'off' time and patient-reported outcomes.
Main Results:
- Ropinirole prolonged release significantly reduced 'off' time compared to placebo.
- More patients on ropinirole prolonged release achieved a 20% reduction in 'off' time versus immediate release.
- The prolonged-release formulation demonstrated fewer plasma concentration fluctuations.
Conclusions:
- Once-daily ropinirole prolonged release is an effective treatment for advanced Parkinson's disease.
- It offers improved pharmacokinetic profiles and comparable efficacy to immediate-release formulations.
- Adverse events were consistent with other non-ergoline dopamine agonists.
More Related Videos
05:51Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
06:25Paw-Print Analysis of Contrast-Enhanced Recordings (PrAnCER): A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits
Published on: August 12, 2019
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...